Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified phase I trial

Cancer

Volumn 89, Issue 3, 2000, Pages 534-542

  Socinski, Mark A ^a,c   Rosenman, Julian G ^a   Schell, Michael J ^a   Halle, Jan ^a   Russo, Suzanne ^a   Rivera, M Patricia ^a   Clark, Jay ^a   Limentani, Steven ^b   Fraser, Robert ^b   Mitchell, William ^b   Detterbeck, Frank C ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Carolinas Medicine Center   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Combined modality therapy; Computer assisted radiotherapy planning; Conformal radiotherapy; Nonsmall cell lung carcinoma; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE;

EID: 0034255290     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000801)89:3<534::aid-cncr8>3.0.co;2-%23     Document Type: Article

References (20)

1. Cancer statistics, 1999
2. Current treatment cf unresectable lung cancer
3. Controversies in the nonsurgical treatment of Stage III non-small cell lung cancer
4. Improved survival in Stage III nonsmall cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
5. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a Phase III trial in regionally, advanced unresectable non-small cell lung cancer
6. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
7. Hyper-fractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for Stage III non-small-cell lung cancer: A randomized study
8. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung cancer: An analysis of a randomized trial in 353 patients
9. ASTRO plenary: Effects of chemotherapy on locally advanced non-small cell lung cancer. A randomized study of 353 patients
10. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small-cell lung cancer
11. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A Phase II toxicity, response, and survival analysis
12. Multi-institutional Phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small-cell lung cancer
13. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): Three-year follow-up
14. Induction paclitaxel (taxol) and carboplatin (CB-DCA) followed by concurrent chemotherapy (TRT-CT) in unresectable, locally advanced non-small cell lung carcinoma (NSCLC): Report of FCCC 94-001
15. IIB or not IIB: The current question in staging in non-small cell lung cancer
16. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
17. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable Stage III non-small cell lung cancer
18. Image registration: An essential part of radiation therapy treatment planning
19. Dose escalation in non-small cell lung cancer using conformal 3-dimensional radiation therapy (C3DRT): Update of a Phase I trial